PE20141906A1 - Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento - Google Patents
Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamientoInfo
- Publication number
- PE20141906A1 PE20141906A1 PE2014001406A PE2014001406A PE20141906A1 PE 20141906 A1 PE20141906 A1 PE 20141906A1 PE 2014001406 A PE2014001406 A PE 2014001406A PE 2014001406 A PE2014001406 A PE 2014001406A PE 20141906 A1 PE20141906 A1 PE 20141906A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- esketamine
- resistant
- refractory
- depression
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 229960000450 esketamine Drugs 0.000 title abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA EL TRATAMIENTO DE LA DEPRESION REFRACTARIA AL TRATAMIENTO O RESISTENTE AL TRATAMIENTO QUE COMPRENDE ADMINISTRAR i) ESKETAMINA EN UNA CANTIDAD DE 0.01 A 1.5 MG/KG, Y OPCIONALMENTE ii) UN ANTIDEPRESIVO TAL COMO FLUOXETINA, IMIPRAMINA, BUPROPION, VENLAFAXINA O SERTRALINA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261609641P | 2012-03-12 | 2012-03-12 | |
US201261610058P | 2012-03-13 | 2012-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141906A1 true PE20141906A1 (es) | 2014-12-05 |
Family
ID=47913632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001406A PE20141906A1 (es) | 2012-03-12 | 2013-03-12 | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
Country Status (14)
Country | Link |
---|---|
US (2) | US20130236573A1 (es) |
KR (1) | KR20140136982A (es) |
CN (1) | CN104519878A (es) |
CL (1) | CL2014002406A1 (es) |
CO (1) | CO7071129A2 (es) |
CR (1) | CR20140410A (es) |
GT (1) | GT201400191A (es) |
HK (1) | HK1209323A1 (es) |
MX (1) | MX2014010939A (es) |
NI (1) | NI201400104A (es) |
PE (1) | PE20141906A1 (es) |
PH (1) | PH12014501997A1 (es) |
SG (1) | SG11201405530SA (es) |
WO (1) | WO2013138322A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
BR112015022972B1 (pt) | 2013-03-15 | 2023-02-14 | Janssen Pharmaceutica Nv | Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma |
EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
EP3964203A1 (en) | 2013-09-13 | 2022-03-09 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
EP3094312B1 (en) * | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
EP3139943A4 (en) * | 2014-05-06 | 2018-07-18 | Northwestern University | Combinations of nmdar modulating compounds |
MX2017001908A (es) * | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
WO2016044150A1 (en) * | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
EP3240422A1 (en) * | 2014-12-31 | 2017-11-08 | Icahn School of Medicine at Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
WO2016172672A1 (en) * | 2015-04-24 | 2016-10-27 | Icahn School Of Medicine At Mount Sinai | Method for treating suicidal ideation |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
WO2017087691A1 (en) | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
CN110167541A (zh) * | 2016-10-27 | 2019-08-23 | 国立大学法人千叶大学 | (s)-去甲氯胺酮及其盐作为药物的应用 |
EP3641742A2 (en) | 2017-06-23 | 2020-04-29 | Develco Pharma Schweiz AG | Hydroxynorketamine for the use in the treatment of depression |
US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
CN107823195A (zh) * | 2017-11-24 | 2018-03-23 | 无锡市精神卫生中心 | R‑氯胺酮在抑郁症急性期治疗中的应用 |
KR20200113197A (ko) * | 2017-12-22 | 2020-10-06 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 에스케타민 |
HUE058320T2 (hu) * | 2017-12-29 | 2022-07-28 | Celon Pharma Sa | Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén |
BR112020016500A2 (pt) | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea |
CA3099293A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
KR20210028159A (ko) * | 2018-06-27 | 2021-03-11 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하는 방법 |
WO2020027344A1 (en) * | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
EP3628313A1 (en) * | 2018-09-28 | 2020-04-01 | Celon Pharma S.A. | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
AU2020223284A1 (en) * | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
CA3131929A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
US20220226586A1 (en) | 2019-05-31 | 2022-07-21 | Celon Pharma S.A. | An Inhaler For Electronically Supervised Parenteral Administration of a Pharmaceutical Composition |
BR112021024138A2 (pt) | 2019-05-31 | 2022-01-11 | Celon Pharma Sa | Sistema para administração supervisionada eletronicamente de uma composição farmacêutica |
JP2022546456A (ja) * | 2019-08-28 | 2022-11-04 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン |
AU2020345050A1 (en) * | 2019-09-13 | 2021-09-16 | Janssen Pharmaceuticals, Inc. | Intranasal administration of esketamine |
AU2021282067A1 (en) * | 2020-05-28 | 2023-02-02 | Janssen Pharmaceutica Nv | Methods for treating depression |
WO2023162987A1 (ja) * | 2022-02-22 | 2023-08-31 | 国立大学法人京都大学 | うつ病および/またはうつ状態の治療および/または予防用医薬 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
EP1103256A1 (de) * | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
WO2004010932A2 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
WO2007111880A2 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
KR20090029200A (ko) * | 2006-05-22 | 2009-03-20 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
PL2582366T3 (pl) * | 2010-06-15 | 2016-04-29 | Gruenenthal Gmbh | Kombinacja farmaceutyczna do leczenia bólu |
-
2013
- 2013-03-12 WO PCT/US2013/030476 patent/WO2013138322A1/en active Application Filing
- 2013-03-12 CN CN201380013908.XA patent/CN104519878A/zh active Pending
- 2013-03-12 MX MX2014010939A patent/MX2014010939A/es unknown
- 2013-03-12 KR KR1020147028246A patent/KR20140136982A/ko not_active Application Discontinuation
- 2013-03-12 PE PE2014001406A patent/PE20141906A1/es not_active Application Discontinuation
- 2013-03-12 SG SG11201405530SA patent/SG11201405530SA/en unknown
- 2013-03-12 US US13/795,454 patent/US20130236573A1/en not_active Abandoned
- 2013-12-05 US US14/098,498 patent/US20140093592A1/en not_active Abandoned
-
2014
- 2014-09-04 CR CR20140410A patent/CR20140410A/es unknown
- 2014-09-08 PH PH12014501997A patent/PH12014501997A1/en unknown
- 2014-09-10 CO CO14200330A patent/CO7071129A2/es unknown
- 2014-09-10 NI NI201400104A patent/NI201400104A/es unknown
- 2014-09-11 GT GT201400191A patent/GT201400191A/es unknown
- 2014-09-11 CL CL2014002406A patent/CL2014002406A1/es unknown
-
2015
- 2015-10-14 HK HK15110013.5A patent/HK1209323A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013138322A1 (en) | 2013-09-19 |
US20130236573A1 (en) | 2013-09-12 |
CR20140410A (es) | 2014-11-17 |
PH12014501997A1 (en) | 2014-11-24 |
KR20140136982A (ko) | 2014-12-01 |
US20140093592A1 (en) | 2014-04-03 |
CL2014002406A1 (es) | 2015-01-09 |
CN104519878A (zh) | 2015-04-15 |
CO7071129A2 (es) | 2014-09-30 |
HK1209323A1 (en) | 2016-04-01 |
NI201400104A (es) | 2016-11-30 |
GT201400191A (es) | 2017-07-03 |
MX2014010939A (es) | 2014-11-13 |
SG11201405530SA (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
PH12015501354A1 (en) | Antiviral compounds | |
CL2016002971A1 (es) | Combinación. | |
GT201500312A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
GT201000182A (es) | Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
GT201500021A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
MD4589C1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
BR112015011933A8 (pt) | Composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
UY35210A (es) | Inhibidores de autotaxina | |
GT201400012A (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX2013008850A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
CL2014000428A1 (es) | Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. | |
ECSP13012534A (es) | Composición farmacéutica | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2014000210A1 (es) | Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. | |
DOP2016000253A (es) | Nuevos compuestos | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |